Antifibrotic therapy for the treatment of pulmonary fibrosis

American Journal of the Medical Sciences

Volumn 322, Issue 4, 2001, Pages 213-221

  Lasky, Joseph A ^a,b   Ortiz, Luis A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Collagen; Fibrosis; Lung; Therapy

Indexed keywords

ANTIFIBROTIC AGENT; BETA INTERFERON; COLCHICINE; COLLAGEN; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRONECTIN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; NICOTINIC ACID; PENICILLAMINE; PIRFENIDONE; TAURINE;

CELL PROLIFERATION; CORTICOSTEROID THERAPY; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; INTERSTITIUM; LUNG FIBROSIS; MESENCHYME CELL; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 0034758063     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200110000-00012     Document Type: Review

References (93)

1. Natural history and treated course of usual and desquamative interstitial pneumonia
2. Cryptogenic fibrosing alveolitis: Response to corticosteroid treatment and its effect on survival
3. Idiopathic nonspecific interstitial pneumonia: Prognostic significance of cellular and fibrosing patterns: Survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia
4. New approaches to the treatment of pulmonary fibrosis
5. Idiopathic pulmonary fibrosis: A need for treatment with drugs other than corticosteroids - A role for antibfibrotic agents?
6. Ten-year follow up of 222 patients with idiopathic pulmonary fibrosis (IPF) - A nationwide survey report in Japan
7. Idiopathic pulmonary fibrosis: Current clinical concepts and challenges in management
8. Randomized controlled trial comparing prednisone alone with cyclophosphamide and low dose prednisone in combination in cryptogenic fibrosing alveolitis
9. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective double-blind, randomized, placebo-controlled clinical trial
10. Immunosupressive and cytotoxic pharmacotherapy for pulmonary disorders
11. Approaches to the treatment of pulmonary fibrosis
12. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement
13. Pathobiology of pulmonary fibrosis
14. Contractile cells in normal and fibrotic lung
15. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis
16. Cytokines of the lung
17. Idiopathic pulmonary fibrosis and pulmonary fibrosis in diffuse systemic sclerosis: Two fibrosis with different prognosis
18. The epidemiology of interstitial lung diseases
19. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. The basis of a possible therapeutic approach of the fibrotic disorders
20. Modulation of platelet-derived growth factor B mRNA abundance in macrophages by colchicine and dibutyryl-cAMP
21. In vitro effect of platelet-derived growth factor on fibroproliferation and effect of cytokine antagonists
22. Antiinflammatory and antifibrotic properties of colchicine: Implications for idiopathic pulmonary fibrosis
23. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice
24. Expression of TNF and the necessity for TNF receptors in bleomycin-induced lung injury in mice
25. Downregulation of tumor necrosis factor receptors on macrophages and endothelium cells by microtubule depolymerizing agents
26. Microtubles in transcellular movement of procollagen
27. Pharmacologicalmodulation of human subconjunctival fibroblasts behavior in vitro
28. The effect of colchicine and vinblastine on bleomycin-induced lung fibrosis in rats
29. The protective effect of colchicine on bleomycin-induced pulmonary fibrosis in rats
30. The effect of colchicine on the accumulation of hydroxyproline and on the lung compliance after irradiation
31. Long-term evaluation of colchicine in the treatment of scleroderma
32. Colchicine in the treatment of pulmonary fibrosis
33. Colchicine versus prednisone as treatment of usual interstitial pneumonia
34. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study
35. Idiopathic pulmonary fibrosis. Impact of oxygen and colchicine, prednisone, or no therapy on survival
36. D-Penicillamine pharmacokinetics and action
37. Suggested mode of action of D-penicillamine as an immunosuppressive agent in rheumatoid arthritis
38. Evaluation of antifibrotic drugs in bleomycin-induced pulmonary fibrosis in hamsters
39. The effect of penicillamine on radiation-induced pulmonary lethality in mice
40. Collagen accumulation in irradiated rat lung: Modification by D-penicillamine
41. The effect of D-penicillamine on pulmonary findings in systemic sclerosis
42. D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term follow up study
43. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study
44. D-Penicillamine in the therapy of fibrotic lung diseases
45. Treatment of idiopathic fibrosing alveolitis. Therapeutic experience with azathioprine-prednisolone and D-penicillamine-prednisolone combination therapy
46. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: A controlled clinical trial
47. How interferons fight disease
48. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma
49. Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts
50. Interferon-gamma modulates lung macrophage production of PDGF-BB and fibroblast growth
51. Recombinant gamma, alpha, and beta interferon regulation of human lung fibroblast proliferation
52. Immune interferon is a growth factor for human lung fibroblasts
53. Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-gamma
54. Effects of interferon-gamma on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts
55. Interleukin-6, interferon-gamma, and phospholipid levels in the alveolar lining fluid of human lungs. Profiles in coal worker's pneumoconiosis and idiopathic pulmonary fibrosis
56. Immune mediators increase adherence of T-lymphocytes to human lung fibroblasts
57. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice
58. New strategies for treatment of pulmonary fibrosis
59. Interleukin-4 and interferon-gamma discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets
60. Ry Effect of murine gamma interferon on the cellular responses to bleomycin in mice
61. Effects of gamma-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats
62. Radiation pneumonitis. Bronchoalveolar lavage assessment and modulation by a recombinant cytokine
63. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: Down-regulation of TGF-beta and procollagen I and III gene expression
64. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA)
65. Immunoreactive interleukin 4 and interferon-gamma expression by type II alveolar epithelial cells in interstitial lung disease
66. In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases
67. Treatment of systemic sclerosis with gamma-interferon
68. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis
69. Effects of interferons on proliferation and collagen synthesis of rat palatal wound fibroblasts
70. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts alter short-term exposure to interferons
71. Interferon-β induces metalloproteinase mRNA expression in human fibroblasts
72. Inhibition of collagen lattice contraction by pentoxifylline and interferon-alpha, -beta, and -gamma
73. Feasibility of a trial of interferon beta-1A in the treatment of idiopathic pulmonary fibrosis
74. Amelioration of bleomycin-induced lung fibrosis in hamsters by dietary supplementation with taurine and niacin: Biochemical mechanisms
75. Effects of nicotinamide and niacin on bleomycin-induced acute injury and subsequent fibrosis in hamster lungs
76. Abatement of bleomycin-induced increases in vascular permeability, inflammatory cell infiltration, and fibrotic lesions in hamster lungs by combined treatment with taurine and niacin
77. Procollagen gene expression is down-regulated by taurine and niacin at the transcriptional level in the bleomycin hamster model of lung fibrosis
78. Dietary supplementation with taurine and niacin prevents the increase in lung collagen cross-links in the multidose bleomycin hamster model of pulmonary fibrosis
79. Attenuation of amiodarone-induced lung fibrosis and phospholipidosis in hamsters by taurine and/or niacin treatment
80. Captopril inhibits proliferation of human lung fibroblasts in culture: A potential antifibrotic mechanism
81. Fibrosis, a common pathway to organ failure: Angiotensin II and tissue repair
82. Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides
83. Kinetic alterations of angiotensin-II and nitric oxide in radiation pulmonary fibrosis
84. Radiation-induced endothelial dysfunction and fibrosis in rat lung: Modification by the angiotensin converting enzyme inhibitor CL242817
85. Monocrotaline-induced cardiopulmonary damage in rats: Amelioration by the angiotensin-converting enzyme inhibitor CL242817
86. Captropril reduces collagen and mast cell accumulation in irradiated rat lung
87. Radiation pneumotoxicity in rats: Modification by inhibitors of angiotensin converting enzyme
88. Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis?
89. Pirfenidone inhibits the stimulatory effects of pro-fibrotic cytokines on human lung fibroblasts in vitro
90. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice
91. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters
92. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label phase II study
93. Idiopathic pulmonary fibrosis